Pfizer/Eyetech's Macugen: Advisory Cmte. Wants Long-Term Follow Up

While the committee finds the existing data were sufficient for approval, members call for long-term follow up to address safety concerns and duration of therapy. The committee also recommends labeling address endophthalmitis.